摘要:目的 探讨Ⅲ期可手术乳腺癌新辅助化疗的临床疗效。 方法 将56例Ⅲ期可手术乳腺癌随机分为新辅助化疗组和对照组。新辅助化疗组术前作3周期CTF(CTX+THP+FUDR)化疗，术后补充放疗、化疗;对照组除不做术前化疗外，手术及术后其他治疗相同。 结果 新辅助化疗组临床有效率达65%，且其病理组织学改变较对照组明显。两组5年生存率分别为65.8%和54.7%，新辅助化疗组明显高于对照组(P<0.05)。 结论 新辅助化疗可提高Ⅲ期可手术乳腺癌的临床疗效。

    关键词:乳腺癌;新化疗;临床疗效

    Evaluation on the clinical effect of neo-adjuvant chemotherapy on breast cancer at stage III.

    ZHONG Xiao-jie，LI Gao.

    (Hainan Provincial People's Hospital，Haikou570311，Hainan，P.R.China)

    Abstract:Objective To evaluate the clinical efficacy of the neo-adjuvant chemotherapy(NACT)for operable stageⅢbreast cancer. Methods 56patients with operable stageⅢbreast cancer were randomly divided into two groups the neoadiuvant chenro therapy(NACT)group and the control group.The NACTgroup received a chemotherapy with the regiman of CTF(CTX+THP+FU-DR)for three cycles before operation.The two groups received the same operation and postoperative adjuvant radio-chemotherapy. Results The clinical response rate in NACT group was65%.The histological changes in the NACT group was much obvious than those in the control group.The5-year survival rates(5YSR)were65.8%and54.7% ......